Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.40 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30888463 | 0.98 | KEAP1 (0.47) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| Potassium Ion SCHEMBL9673910 | 0.96 | KEAP1 (0.48) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| SCHEMBL4022653 | 0.96 | KEAP1 (0.48) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| SCHEMBL285412 | 0.88 | KMT2A (0.50) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| Water SCHEMBL28916296 | 0.86 | KMT2A (0.49) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| Potassium Ion SCHEMBL190393 | 0.84 | KMT2A (0.50) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| SCHEMBL5492632 | 0.84 | KMT2A (0.50) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| Tetrabuthylammonium SCHEMBL4016430 | 0.83 | MAPK1 (0.41) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| SCHEMBL4342856 | 0.82 | KEAP1 (0.54) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A | |
| Water SCHEMBL2810011 | 0.81 | KEAP1 (0.48) | KEAP1SMN1; SMN2HRH3EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480155-B2 | Nicking enzymes | LUMIRADX UK LTD. (GB) | 2025-11-25 | — | — | US | claimed |
| CN-119955714-A | Culture solution for improving embryo health degree and embryo culture method | 多能干细胞再生医学科技（广州）有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-115491362-B | Oxidase immobilization method | 可孚医疗科技股份有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-118006125-A | Polyamic acid composition and modified polyamide acid | 比亚迪股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117987407-A | Method for visually screening enzyme mutant with high flux | 淮阴工学院 | 2024-05-07 | — | — | CN | claimed |
| CN-114813288-B | Quick dyeing and positioning method for active oxygen of plant root system | 甘肃农业大学 | 2024-04-12 | — | — | CN | claimed |
| CN-117825721-A | Buffer composition for removing specific interference and application thereof | 江苏三联生物工程股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-115197432-B | Antibacterial/antiviral polymer material and preparation method thereof | 中国科学院长春应用化学研究所 | 2024-03-26 | — | — | CN | claimed |
| CN-114200133-B | Anti-extractable nuclear antigen antibody quality control product and preparation method and application thereof | 深圳市昭蓝生物科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-11865391-B2 | Long-term fire retardant with corrosion inhibitors and methods for making and using same | FRS GROUP, LLC (US) | 2024-01-09 | — | — | US | claimed |
| CN-114200133-A | Anti-extractable nuclear antigen antibody quality control product and preparation method and application thereof | 深圳市昭蓝生物科技有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-113993995-A | Improvements in or relating to nicking enzymes | 卢米拉特英国有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-111224017-B | Quantum dot light-emitting diode and preparation method thereof | TCL科技集团股份有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-112582564-A | Light emitting device and method of manufacturing the same | TCL集团股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-112582565-A | Light emitting device and method of manufacturing the same | TCL集团股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-111224000-A | Quantum dot light-emitting diode and preparation method thereof | TCL集团股份有限公司 | 2020-06-02 | — | — | CN | claimed |
| CN-111223998-A | Quantum dot light-emitting diode and preparation method thereof | TCL集团股份有限公司 | 2020-06-02 | — | — | CN | claimed |
| CN-111224017-A | Quantum dot light-emitting diode and preparation method thereof | TCL集团股份有限公司 | 2020-06-02 | — | — | CN | claimed |
| US-20120015044-A1 | FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS | TREIBER, Laszlo (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012009290-A2 | FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS | TREIBER LASZLO (US) | 2012-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015044-A1 | FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS | AOC1, AOC3, GPR17 | CA1 1818/4885CA2 2958/4885KEAP1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.